T. Kobayashi

OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study

S. Vermeire, G. D'Haens, F. Baert, 2020 .

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease

T. Hibi, K. Isobe, S. Okamoto, 2008, Gut.

Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study.

G. D'Haens, L. Peyrin-Biroulet, R. Panaccione, 2022, Gastroenterology & hepatology.

Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.

G. D'Haens, V. Arora, C. Milch, 2022, Gastroenterology & hepatology.

P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION

A. Sturm, D. Laharie, A. Oortwijn, 2023, Journal of Crohn's and Colitis.

DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

S. Travis, R. Panaccione, A. Walsh, 2023, Journal of Crohn's and Colitis.

DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial

M. Nojima, M. Saruta, M. Matsuura, 2022, Journal of Crohn's & Colitis.